Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Feb 23 04:00PM ET
0.7945
Dollar change
-0.2021
Percentage change
-20.28
%
Index- P/E- EPS (ttm)-0.32 Insider Own2.20% Shs Outstand256.50M Perf Week6.50%
Market Cap203.79M Forward P/E- EPS next Y-0.29 Insider Trans0.00% Shs Float250.87M Perf Month45.43%
Income-75.52M PEG- EPS next Q-0.06 Inst Own10.25% Short Float9.45% Perf Quarter105.30%
Sales0.00M P/S- EPS this Y25.44% Inst Trans-2.91% Short Ratio5.23 Perf Half Y68.65%
Book/sh0.23 P/B3.49 EPS next Y-1.18% ROA-79.11% Short Interest23.71M Perf Year-21.34%
Cash/sh0.21 P/C3.81 EPS next 5Y- ROE-98.28% 52W Range0.34 - 1.28 Perf YTD38.17%
Dividend Est.- P/FCF- EPS past 5Y63.63% ROI-119.78% 52W High-37.93% Beta3.47
Dividend TTM- Quick Ratio5.08 Sales past 5Y-25.00% Gross Margin- 52W Low130.29% ATR (14)0.11
Dividend Ex-Date- Current Ratio5.08 EPS Y/Y TTM7.95% Oper. Margin0.00% RSI (14)57.21 Volatility25.71% 11.97%
Employees84 Debt/Eq0.11 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price6.33
Option/ShortYes / Yes LT Debt/Eq0.08 EPS Q/Q45.45% Payout- Rel Volume3.69 Prev Close1.00
Sales Surprise- EPS Surprise14.29% Sales Q/Q- EarningsNov 09 BMO Avg Volume4.53M Price0.79
SMA2020.90% SMA5038.65% SMA20058.47% Trades Volume16,715,916 Change-20.28%
Date Action Analyst Rating Change Price Target Change
Mar-01-23Upgrade Chardan Capital Markets Neutral → Buy $3.50
Aug-23-22Initiated Mizuho Buy $5
Jun-15-22Resumed ROTH Capital Buy $8
Jun-02-22Initiated Cantor Fitzgerald Overweight $4.50
Jul-26-21Initiated Noble Capital Markets Outperform
Jun-11-21Downgrade ROTH Capital Buy → Neutral $10 → $6
May-07-21Downgrade Cantor Fitzgerald Overweight → Neutral
Feb-09-21Downgrade Chardan Capital Markets Buy → Neutral $0.70 → $13
Feb-04-21Upgrade H.C. Wainwright Neutral → Buy $4.50
Feb-22-24 04:05PM
12:56PM
Feb-21-24 04:05PM
Feb-20-24 10:26AM
Feb-14-24 07:30AM
08:00AM Loading…
Jan-31-24 08:00AM
Jan-16-24 07:30AM
Dec-21-23 06:30AM
Dec-19-23 07:30AM
Dec-13-23 07:30AM
Nov-29-23 07:30AM
Nov-10-23 01:54PM
07:30AM
02:07AM
Nov-09-23 11:45AM
08:38AM Loading…
08:38AM
07:00AM
06:30AM
Nov-07-23 07:45AM
Nov-02-23 07:30AM
Oct-10-23 09:58AM
06:30AM
Oct-04-23 07:00AM
Sep-29-23 07:30AM
Sep-27-23 07:30PM
Sep-21-23 07:30AM
Sep-20-23 08:00AM
Sep-13-23 08:15AM
Sep-12-23 07:30PM
Aug-24-23 09:48AM
02:05AM Loading…
Aug-23-23 02:05AM
Aug-22-23 12:00PM
Aug-21-23 04:32PM
Aug-18-23 04:39PM
Jul-25-23 08:58PM
Jul-13-23 07:00AM
Jun-30-23 08:00AM
Jun-09-23 04:05PM
Jun-05-23 07:02AM
May-25-23 02:00PM
May-24-23 08:36AM
May-23-23 04:01PM
08:00AM
May-05-23 03:00PM
07:17AM
07:00AM
Apr-28-23 07:00AM
Apr-27-23 07:25AM
Apr-26-23 06:30AM
Apr-20-23 08:00AM
Apr-14-23 01:47PM
07:45AM
Apr-11-23 06:20PM
Mar-31-23 08:15AM
Mar-27-23 08:00AM
Mar-07-23 08:00AM
Mar-06-23 07:02AM
Mar-02-23 07:02AM
Mar-01-23 06:16AM
02:17AM
Feb-28-23 06:04PM
04:00PM
07:00AM
Feb-27-23 05:57PM
Feb-17-23 08:00AM
Feb-16-23 05:30AM
Feb-15-23 04:30PM
Feb-04-23 05:30AM
Feb-03-23 11:18AM
Feb-01-23 01:55PM
08:00AM
Jan-31-23 08:00AM
Jan-29-23 07:00AM
Jan-26-23 05:21AM
Jan-23-23 05:21AM
Jan-11-23 07:03AM
Jan-09-23 08:33AM
06:22AM
06:16AM
06:00AM
Dec-29-22 03:39PM
Dec-25-22 03:58PM
Dec-16-22 06:30AM
Dec-15-22 05:15PM
Dec-13-22 08:00AM
Dec-07-22 08:00AM
Nov-28-22 07:30AM
Nov-17-22 09:23AM
Nov-09-22 06:16PM
Nov-08-22 06:30PM
01:00PM
07:30AM
Nov-07-22 08:17AM
Nov-02-22 05:21AM
Nov-01-22 07:42PM
Oct-27-22 07:30AM
Oct-19-22 07:30AM
Oct-12-22 05:37PM
Oct-06-22 09:25AM
08:00AM
Ocugen, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies to cure eye diseases. Its product pipeline candidates include OCU400, OCU410, OCU200, and COVAXIN. The firm's modifier gene therapy platform is engaged in addressing retinal diseases, including retinitis pigmentosa, leber congenital amaurosis, and dry age-related macular degeneration. The company was founded by Shankar Musunuri and Uday B. Kompella in 2013 and is headquartered in Malvern, PA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Zhang JungeDirectorJun 14Buy0.50200,27899,9991,077,182Jun 16 04:22 PM